ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
Metabolic Disorders
-
-
Wave’s stock crashes 50% on Phase I obesity data
Wave Life Sciences’ stock has crashed by nearly 50% after its Phase I obesity trial showed low levels of weight…
-
Lilly’s triple G agonist succeeds in Phase III diabetes trial
Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone receptor agonist has met its primary endpoints in…
-
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial, but the…
-
Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II…
-
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial
Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The Phase III REDEFINE…
-
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer’s recently acquired weight loss injection has shown to maintain weight loss after a switch from weekly to monthly dosing…
-
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Novo Nordisk’s CagriSema has outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight…
-
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial
Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound (tirzepatide) has shown benefit in interim…
-
MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial
MetaVia’s dual oxyntomodulin (OXM) analogue agonist has met the endpoints in a Phase Ib trial evaluating the drug for weight…
